|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02666 UNI MEDICAL
Nominal 
5.960 +0.150 (+2.582%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 14,939,517 | 9.339% | 13,663,485 | 13,650,203 | 12,073,172 | 9,914,273 |
| Cost of Sales | (9,909,481) | 9.236% | (9,071,645) | (9,078,344) | (7,578,878) | (5,714,834) |
| Gross Profit | 5,030,036 | 9.543% | 4,591,840 | 4,571,859 | 4,494,294 | 4,199,439 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (331,323) | 2.583% | (322,980) | (192,099) | (307,139) | (318,235) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | (519) | (1,624) | (1,154) | (942) | |
| Share of Results of Asso. & JCEs | (9,092) | -- | 26,564 | 6,380 | 13,462 | 13,865 | |
| Profit / (Loss) before Taxation | 3,019,148 | 3.854% | 2,907,119 | 2,866,213 | 2,703,274 | 2,691,808 | |
| Taxation | (701,556) | 8.134% | (648,785) | (667,141) | (617,326) | (661,339) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (108,641) | -29.626% | (154,377) | (88,735) | (126,128) | (82,739) | |
| Others | (52,188) | -27.734% | (72,217) | (89,419) | (71,403) | (112,497) | |
| Profit / (Loss) Attributable to Shareholders | 2,156,763 | 6.153% | 2,031,740 | 2,020,918 | 1,888,417 | 1,835,233 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 27,404 | -- | (4,797) | (45,075) | (38,517) | (27,564) |
| Depreciation & Amortisation | 788,457 | 30.917% | 602,257 | 508,665 | 442,049 | 319,464 |
| Directors' Emoluments | 8,215 | -6.499% | 8,786 | 13,785 | 14,631 | 12,354 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 113.000 | 5.607% | 107.000 | 107.000 | 100.000 | 99.000 |
| DPS (cts) | 31.809 | -- | 32.300 | 31.740 | 29.788 | 29.264 |
| Dividend Payout Ratio (%) | 28.149% | -- | 30.187% | 29.664% | 29.788% | 29.559% |
| Cash flow per share ($) | 3.027 | -- | 0.602 | 2.640 | 1.074 | (0.753) |
| NBV per share ($) | 9.572 | -- | 9.058 | 8.248 | 7.351 | 6.888 |
| Remarks: | Real time quote last updated: 27/03/2026 14:37 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,156,763 |
| %Change | 6.153% |
| EPS / (LPS) | RMB 1.130 |
| NBV Per Share (¥) | RMB 9.572 |